05Nov 2021
Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Over 99% of the EMPA‐REG OUTCOME trial participants had established cardiovascular disease (CVD). We aimed to investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin vs dipeptidyl peptidase‐4 inhibitor (DPP‐4i) across the broad spectrum of cardiovascular risk. In a population‐based cohort study we identified 39,072 pairs of 1:1 propensity score‐matched adult patients with T2D initiating empagliflozin or DPP‐4i, using data from 2 U.S. commercial insurance databases and Medicare between 08/2014‐09/2017. Primary outcomes were a composite of myocardial infarction (MI)/stroke, and hospitalization for heart failure (HHF). Safety outcomes were bone fractures, lower‐limb amputations (LLA), diabetic ketoacidosis (DKA), and acute kidney injury (AKI). We estimated pooled hazard ratios (HR) and 95% CI adjusting for >140 baseline covariates...

  • #family health

Like

Save

Share